 | This articlemay rely excessively on sourcestoo closely associated with the subject, potentially preventing the article from beingverifiable andneutral. Please helpimprove it by replacing them with more appropriatecitations toreliable, independent sources.(December 2018) (Learn how and when to remove this message) |
 | |
| Company type | Aktiengesellschaft |
|---|---|
| Founded | 1997 |
| Headquarters | Berlin,Germany |
Key people |
|
Number of employees | 10(2017)[1] |
| Website | www.tmepharma.com |
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 inBerlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris (ALTME)and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller (vfa).
TME Pharma develops drugs using technology yieldingL-RNA molecules, which are of mirror-image configuration compared to naturally occurringD-RNA molecules. The company calls these agents Spiegelmers,[2][3] fromSpiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNAnuclease enzymes.[4]
Some Spiegelmer candidates were in clinical trials.
A Spiegelmer (NOX-A12, olaptesed pegol) was under development as a combination therapy for a number of cancer indications. NOX-A12 targetsCXCL12 (C-X-C Chemokine Ligand 12), a key chemokine protein. Favorable results were reported in October 2018 during the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York, NY, USA.[5][6][7][8]
A different Spiegelmer (NOX-E36, emapticap pegol) was tested for the treatment of progressivediabetic nephropathy.[9] Favorable results were reported in June 2014 in a company press release.[10] NOX-E36 targetsMCP-1, also calledCCL2.[4]
A third Spiegelmer (NOX-H94, lexaptepid pegol) was in a clinical trial for the treatment ofanemia of chronic disease.[11][12]